Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: Aspects of the present disclosure relate to ingesting event data into a discoverable event stream using a common schema to assign timeseries properties to the event data. These techniques may include receiving a first event of a pre-processed event stream, the first event including a plurality of event data fields representing an occurrence of the first event, and determining timing information based on the plurality of event data fields representing the occurrence of the first event. In addition, the techniques may include generating, based on combining the plurality of event data fields and the timing information, a second event of a discoverable event stream corresponding to the pre-processed event stream, and generating, within a time series of the discoverable event stream, based on the timing information and an event field of the plurality of event data fields, a time series entry corresponding to the second event.

Abstract: In some implementations, a dot projector optic may include a collimating lens; a fisheye lens; and a dot aberration correction element disposed between the collimating lens and the fisheye lens. An input to the fisheye lens, from the dot aberration correction element, may be associated with a first field of view angle. An output from the fisheye lens may be associated with a second field of view angle that is larger than the first field of view angle.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.

Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.